Anticoagulation in Patients with Liver Cirrhosis / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 218-222, 2017.
Artigo
em Coreano
| WPRIM
| ID: wpr-51512
ABSTRACT
Cirrhotic patients have bleeding tendencies due to the lack of coagulation factors and thrombocytopenia. However, decreased levels of procoagulants are also accompanied by decreased levels of natural anticoagulants. However, there have been contrasting reports. It has been reported that patients with cirrhosis are at risk for thrombotic complications, including portal vein thrombosis and venous thromboembolism. Physicians consider active anticoagulation for prophylaxis and treatment of portal vein thrombosis and/or venous thromboembolism in cirrhotic patients with high risk of thrombosis. Concurrently, there are safety concerns regarding the risk of bleeding from anticoagulants in people with advanced liver disease. Further prospective studies are required to determine not only if cirrhotic patients benefit from receiving anticoagulation therapy for preventing thrombotic complications, but also to determine which prophylactic regimen is most appropriate.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Trombocitopenia
/
Trombose
/
Fibrose
/
Fatores de Coagulação Sanguínea
/
Estudos Prospectivos
/
Trombose Venosa
/
Tromboembolia Venosa
/
Hemorragia
/
Fígado
/
Cirrose Hepática
Tipo de estudo:
Estudo observacional
Limite:
Humanos
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS